Recursion Pharmaceuticals, Inc. $RXRX Position Reduced by QRG Capital Management Inc.

QRG Capital Management Inc. cut its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 32.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 19,366 shares of the company’s stock after selling 9,149 shares during the quarter. QRG Capital Management Inc.’s holdings in Recursion Pharmaceuticals were worth $98,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of RXRX. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Recursion Pharmaceuticals by 183.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,408,524 shares of the company’s stock valued at $33,901,000 after buying an additional 4,149,346 shares in the last quarter. ARK Investment Management LLC lifted its stake in Recursion Pharmaceuticals by 7.6% during the first quarter. ARK Investment Management LLC now owns 34,815,502 shares of the company’s stock valued at $184,174,000 after buying an additional 2,469,104 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Recursion Pharmaceuticals in the first quarter worth approximately $10,118,000. Kinnevik AB publ lifted its position in shares of Recursion Pharmaceuticals by 12.8% in the first quarter. Kinnevik AB publ now owns 13,434,171 shares of the company’s stock worth $71,067,000 after purchasing an additional 1,528,503 shares in the last quarter. Finally, Jump Financial LLC lifted its position in shares of Recursion Pharmaceuticals by 4,289.8% in the first quarter. Jump Financial LLC now owns 592,353 shares of the company’s stock worth $3,134,000 after purchasing an additional 578,859 shares in the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Najat Khan sold 36,599 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $5.52, for a total value of $202,026.48. Following the transaction, the insider owned 668,197 shares in the company, valued at approximately $3,688,447.44. This represents a 5.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 8.43% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on RXRX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Wednesday, October 8th. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, September 11th. Finally, Morgan Stanley started coverage on shares of Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They issued an “equal weight” rating and a $5.00 price target for the company. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $7.25.

Recursion Pharmaceuticals Trading Down 10.0%

NASDAQ:RXRX opened at $5.32 on Monday. The stock’s 50 day moving average price is $5.07 and its 200 day moving average price is $5.10. Recursion Pharmaceuticals, Inc. has a 52 week low of $3.79 and a 52 week high of $12.36. The company has a market capitalization of $2.31 billion, a P/E ratio of -2.99 and a beta of 0.91. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.58 and a current ratio of 3.58.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The firm had revenue of $19.10 million during the quarter, compared to analyst estimates of $15.38 million. During the same quarter in the prior year, the company posted ($0.40) EPS. The company’s quarterly revenue was up 33.3% on a year-over-year basis. On average, research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.